WASHINGTON (thehill): The Food and Drug Administration (FDA) on Monday granted approval for the first new Alzheimer’s treatment since 2003, greenlighting Biogen’s drug aducanumab.
In a statement, the FDA said it decided to use an “accelerated approval” pathway to make drugs and therapies available to patients enduring “serious diseases where there is an unmet need” and “an expectation of clinical benefit.”
“In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of Aduhelm for patients with Alzheimer’s disease outweighed the risks of the therapy,” the FDA added.
NEW YORK: Her story is at the heart of the hush money criminal trial against…
GAZA : Hamas official Osama Hamdan warned on Tuesday that if Israel’s military aggression continues…
BERLIN: Police have broken up a protest by several hundred pro-Palestinian activists who occupied a…
WASHINGTON (AFP): TikTok and its Chinese parent company ByteDance filed a legal challenge against the…
F.P. Report ISLAMABAD: Prime Minister Shehbaz Sharif on Tuesday said that the visit of Saudi…
This website uses cookies.